Drug Class Review: Second Generation Antidepressants: Final Report Update 4 [Internet]

Gerald Gartlehner; Laura C Morgan; Patricia Thieda; Kylie Thaler; Richard A Hansen; Bradley Gaynes; Kathleen N Lohr; Timothy S Carey

Drug Class Review: Second Generation Antidepressants: Final Report Update 4 [Internet]

Review

Portland (OR): Oregon Health & Science University; 2008 Oct.

Authors

Gerald Gartlehner¹, Laura C Morgan¹, Patricia Thieda¹, Kylie Thaler¹, Richard A Hansen¹, Bradley Gaynes¹, Kathleen N Lohr¹, Timothy S Carey¹

Affiliation

¹ RTI-UNC Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, 725 Airport Road, CB# 7590, Chapel Hill, NC 27599-7590, Tim Carey, MD, MPH, Director.

PMID: 21089243
Bookshelf ID: NBK47146

Excerpt

Axis I psychiatric disorders such as depressive disorder, anxiety disorder, adjustment disorder, and premenstrual disorders are serious disabling illnesses. Newer treatments for these disorders include selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and other second-generation drugs. The purpose of this review is to evaluate the comparative evidence on benefits and harms of these medications in people with depression to help policymakers and clinicians make informed choices about the use of selective serotonin reuptake inhibitors and newer antidepressants.

Sections

Publication types

Review

Grants and funding

The Drug Effectiveness Review Project, made up of 15 organizations including 14 state Medicaid agencies, commissioned and funded this report. These organizations selected the topic of the report and had input into its Key Questions. Content and conclusions of the report were determined entirely by researchers at the Evidence-based Practice Center. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in the report.